B-CELL LYMPHOMA-2 RECEPTOR EXPRESSION IN HUMAN BREAST CANCER


  • V. Fulga Department of Histology, Cytology and Embryology, “Nicolae Testemitanu” State University of Medicine and Pharmacy, Republic of Moldova

Abstract

B-CELL LYMPHOMA-2 RECEPTOR EXPRESSION IN HUMAN BREAST CANCER

References

1. Allred D.C., Harvey J.M., Berardo M., Clark G.M. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod. Pathol. 1998; 11:155-168.



2. Wolff A.C., Hammond M.E., Hicks D.G., et al. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. J. Clin. Oncol. 2013; 31(31):3997- 4013.



3. Azoulay S., Laé M., Fréneaux P., Merle S. et al. KIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favorable outcome. Mod. Pathol. 2005; 18(12):1623-31.



4. Callagy G.M., Pharoah P.D., Pinder S.E. et al. BCL2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. Clin. Cancer. Res. 2006; 12(8):2468–2475.



5. Ermiah E., Buhmeida A., Khaled B.R. et al. Prognostic value of BCL2 expression among women with breast cancer in Libya. Tumour Biol. 2013; 34(3):1569-78.
Published
2017-12-27
How to Cite
Fulga, V. (2017). B-CELL LYMPHOMA-2 RECEPTOR EXPRESSION IN HUMAN BREAST CANCER. Biological Markers in Fundamental and Clinical Medicine (scientific Journal), 1(3), 32-35. https://doi.org/10.29256/01.03.2017.escbm11
Section
Selected abstracts